Tenax Therapeutics, Inc. (TENX) Stock Price

TENXStock

$1.36−80.06%52W

Market Cap$50.90M

P/E—

PEG Ratio1.44

Div yield—

Beta1.01

TENX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-100.70%

Price vs S&P 500 (4W)-26.33%

PEG Ratio1.44

VGM Score7.03

Book Value / Share (Quarterly)$3.56

P/TBV (Annual)3.79x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.44

Price vs S&P 500 (YTD)-100.77%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-10115.82%

EPS (TTM)$-1.47

10-Day Avg Trading Volume2.24M

EPS Excl Extra (TTM)$-1.47

EPS (Annual)$-1.34

ROI (Annual)-54.19%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-12872.94%

Cash / Share (Quarterly)$3.69

ROA (Last FY)-50.47%

Revenue Growth TTM (YoY)-82.93%

EBITD / Share (TTM)$-1.55

ROE (5Y Avg)-337.11%

Operating Margin (TTM)-10390.47%

Cash Flow / Share (Annual)$-3.84

P/B Ratio0.45x

P/B Ratio (Quarterly)3.40x

Net Income / Employee (Annual)$-3,757,100

EV / Revenue (TTM)-1360.64x

Net Interest Coverage (TTM)-320.28x

ROA (TTM)-57.42%

EPS Incl Extra (Annual)$-1.34

Current Ratio (Annual)14.56x

Quick Ratio (Quarterly)14.65x

3-Month Avg Trading Volume4.40M

52-Week Price Return-80.06%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$10164.00

P/S Ratio (Annual)1032.38x

Asset Turnover (Annual)0.00x

52-Week High$19.40

Operating Margin (5Y Avg)-10572.22%

EPS Excl Extra (Annual)$-1.34

Tangible BV CAGR (5Y)47.56%

26-Week Price Return-90.80%

Quick Ratio (Annual)13.78x

13-Week Price Return-91.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)15.07x

Enterprise Value$-67.08M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-55.21%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-28563.49%

Cash / Share (Annual)$10.47

3-Month Return Std Dev203.50%

Gross Margin (5Y Avg)57.92%

Net Income / Employee (TTM)$-4,633,100

ROE (Last FY)-54.19%

Net Interest Coverage (Annual)-17.63x

EPS Basic Excl Extra (Annual)$-1.34

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.47

Receivables Turnover (Annual)0.00x

ROI (TTM)-61.55%

P/S Ratio (TTM)1032.38x

Pretax Margin (5Y Avg)-12872.94%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$17141.00

Price vs S&P 500 (52W)-95.59%

Year-to-Date Return-88.84%

5-Day Price Return-25.68%

EPS Normalized (Annual)$-1.34

ROA (5Y Avg)-201.92%

Net Profit Margin (Annual)-28563.49%

Month-to-Date Return-28.04%

Cash Flow / Share (TTM)$-0.49

EBITD / Share (Annual)$-1.44

Operating Margin (Annual)-30054.16%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-292.37%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.47

P/TBV (Quarterly)1.04x

P/B Ratio (Annual)0.78x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-10115.82%

Book Value / Share (Annual)$10.42

Price vs S&P 500 (13W)-94.11%

Beta1.01x

Revenue / Share (TTM)$0.00

ROE (TTM)-61.55%

52-Week Low$1.31

gGradeF

mGradeF

vgmGradeF

TENX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 31, 2026	-$0.36	-$0.35	+3.16%(+$0.01)
Q1 2026	May 12, 2026	-$0.40	-$0.35	+11.77%(+$0.05)
Q4 2025	Mar 10, 2026	-$0.41	-$0.38	+8.43%(+$0.03)
Q3 2025	Nov 12, 2025	-$1.12	-$0.40	+64.41%(+$0.72)
Q2 2025	Aug 13, 2025	-$0.45	-$0.27	+39.66%(+$0.18)

TENX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.33

4.25

3.88

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
TENXTenax Therapeutics, Inc.	—	F	F	1032.4x	-82.9%	100.0%	—	$1.36
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Tenax Therapeutics, Inc.

Tenax Therapeutics is a specialty pharmaceutical company focused on cardiovascular and pulmonary diseases with high unmet medical needs. The company's lead asset is levosimendan (North American rights), currently in Phase 2 development for pulmonary hypertension associated with heart failure with preserved ejection fraction.

TENX Insider Transactions

BuySep 16, 2026
DOOGAN DECLAN
Director
Shares: 53,000Value: $101,760
BuySep 15, 2026
GIORDANO CHRISTOPHER THOMAS
Chief Executive Officer
Shares: 10,850Value: $20,087
BuySep 11, 2026
STAAB THOMAS R II
Chief Financial Officer
Shares: 5,675Value: $10,981
BuySep 3, 2026
ADAR1 CAPITAL MANAGEMENT LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 900,000Value: $1.60M
BuySep 2, 2026
ADAR1 CAPITAL MANAGEMENT LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 770,333Value: $1.38M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

SAFXXCF Global, Inc. Class A Common StockIndustrial Chemicals
SGMOSangamo Therapeutics, Inc. Common StockBiological Products
WNWMeiwu Technology Company Limited Ordinary SharesSoap & Detergents
ELOXEloxx Pharmaceuticals, Inc. Common StockBiological Products
CRBUCaribou Biosciences, Inc. Common StockBiological Products
LONALeonaBio, Inc. Common StockBiological Products
ZONEZone Frontier Inc.Cleaning & Polishing Products
INKTMiNK Therapeutics, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$1.31

High$19.40